ClinicalTrials.gg
Active, not recruitingNCT01659606Updated Mar 27, 2026

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

A Phase 2 interventional study of alemtuzumab and Fludarabine in Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome and Revesz Syndrome, sponsored by Boston Children's Hospital. Active, not recruiting at 13 sites in 3 countries. Open to participants aged 30 Days to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Boston Children's Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
30 Days to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Dyskeratosis Congenita with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Dyskeratosis Congenita · United States.

Planned enrollment
5th of 13
40 · median 36
Started
2012
the only one that year
Phase 2
5 of 17
3 open now
Registered
6th of 17
by date
Lead sponsor
2 of 17
Boston Children's Hospital

Among the 17 studies in Dyskeratosis Congenita with a site in United States, this one is the 5th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2012, is one of 5 in phase 2, and was the 6th registered.

Dyskeratosis Congenita

22 studies on the registry are indexed under Dyskeratosis Congenita; 10 are open to participants now.

Browse Dyskeratosis Congenita studies →

Open to participants now

8 of the 17 studies in Dyskeratosis Congenita with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Dyskeratosis Congenita studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.

This study: 30 Days to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Dyskeratosis Congenita with a site in United States, or all of them as a file.
02

Study summary

Dyskeratosis congenita is a disease that affects numerous parts of the body, most typically causing failure of the blood system. Lung disease, liver disease and cancer are other frequent causes of illness and death. Bone marrow transplantation (BMT) can cure the blood system but can make the lung and liver disease and risk of cancer worse, because of DNA damaging agents such as alkylators and radiation that are typically used in the procedure. Based on the biology of DC, we hypothesize that it may be possible to avoid these DNA damaging agents in patients with DC, and still have a successful BMT. In this protocol we will test whether a regimen that avoids DNA alkylators and radiation can permit successful BMT without compromising survival in patients with DC.

Read the detailed description

Dyskeratosis congenita (DC) is an inherited multisystem disorder, which classically presents with a clinical triad of skin pigment abnormalities, nail dystrophy, and oral leukoplakia. DC is part of a spectrum of telomere biology disorders, which include some forms of inherited idiopathic aplastic anemia, myelodysplastic syndrome, and pulmonary fibrosis and the congenital diseases Hoyeraal-Hreidarsson syndrome and Revesz syndrome. Progressive bone marrow failure (BMF) occurs in more than 80% of patients under 30 years of age and is the primary cause of morbidity and mortality, followed by pulmonary failure and malignancies. Allogeneic hematopoietic cell transplantation (HCT) is curative for the hematological defects, but several studies have demonstrated poor outcomes in DC patients due to increased early and late complications. A predisposition to pulmonary failure, vascular disease and secondary malignancies may contribute to the high incidence of fatal complications following HCT in DC patients, and provides an impetus to reduce exposure to chemotherapy and radiotherapy in preparative regimens. Recent studies suggest that fludarabine-based conditioning regimens provide stable engraftment and may avoid the toxicities seen after HCT for DC, but studies to date are limited to case reports, retrospective studies and a single prospective trial. In this study, we propose to prospectively evaluate the efficacy of a fludarabine- and antibody-based conditioning regimen in HCT for DC patients, with the goals of maintaining donor hematopoiesis and transfusion independence while decreasing early and late complications of HCT for DC.

03

Conditions studied

  • Dyskeratosis Congenita
  • Hoyeraal Hreidarsson Syndrome
  • Revesz Syndrome
  • Aplastic Anemia

Keywords

  • dyskeratosis congenita
  • bone marrow failure
  • aplastic anemia
  • bone marrow transplantation
  • reduced intensity conditioning
  • campath
  • fludarabine
  • telomere
04

Who can participate

Ages eligible
30 Days to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bone marrow hypocellular for age
  • Moderate or severe aplastic anemia defined by one of the following: peripheral blood neutrophils \< 0.5 x 10\^9/L; \< 30 x 10\^9/L or platelet transfusion dependence; reticulocytes \< 50 x 10\^9/L in anemic patients or red cell transfusion dependence
  • Diagnosis of dyskeratosis congenita based on clinical triad of abnormalities of skin pigmentation, nail dystrophy, oral leukoplakia; OR one of clinical triad and presence of two or more associated features; OR a pathogenic mutation in DKC1,TERC, TERT, NOP10, NHP2, TCAB1, TINF2, CTC1, PARN, RTEL1, ACD, NAF1, STN1, or ZCCHC8, as reported by a CLIA-approved laboratory; OR age-adjusted mean telomere length \< 1%ile in peripheral blood lymphocytes as reported by a CLIA-approved laboratory; OR Hoyeraal-Hreidarsson syndrome; OR Revesz syndrome
  • Availability of a related or unrelated donor with a 7/8 or 8/8 match for HLA-A, B, C, and DRB1.
  • Patient and/or legal guardian must be able to sign .
  • Donor must provide a marrow allograft.
  • Diagnosis of Fanconi anemia must be excluded by mitomycin C or diepoxybutane chromosomal breakage testing on peripheral blood at a CLIA-approved laboratory (not required for patients with a genetic mutation consistent with DC)
  • Adequate renal function with equal to or greater than 30 ml/min/1.73 m2

Exclusion criteria

Exclusion Criteria:

  • Clonal cytogenetic abnormalities associated with MDS or AML on bone marrow examination.
  • /Lansky performance status \< 40.
  • Uncontrolled bacterial, viral or fungal infections.
  • Positive test for the (HIV).
  • Pregnancy or breastfeeding.
  • Known severe or life-threatening allergy or intolerance to fludarabine, alemtuzumab, mycophenolate mofetil or both cyclosporine and tacrolimus.
  • Positive patient anti-donor HLA antibody, which is deemed .
  • Prior allogeneic marrow or stem cell transplantation.
  • Prior solid organ transplantation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    alemtuzumab/fludarabine conditioning

    alemtuzumab/fludarabine conditioning; calcineurin-inhibitor/mycophenolate mofetil GVHD prophylaxis

    Biological: alemtuzumab · Drug: Fludarabine · Drug: Cyclosporins · Drug: Mycophenolate mofetil · Drug: Tacrolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Primary engraftment

    Time frame: Up to day +100 post-BMT

Secondary outcomes

  1. Survival to day+100 post-BMT

    Time frame: Up to day+100 post-BMT

  2. Viral reactivation and infection

    Number of participants with DNA virus (cytomegalovirus, Epstein Barr virus, or adenovirus) reactivation/infection detected by PCR screening will be reported.

    Time frame: Up to day +100 post-BMT

  3. Treatment related adverse events as assessed by CTCAE version 4.0

    Time frame: Up to 1 year post-BMT

  4. Secondary graft failure

    Time frame: Up to 15 years post-BMT

  5. Acute and chronic graft-versus-host disease (GVHD)

    Time frame: Up to 15 years post-BMT

  6. Engraftment monitoring (chimerism)

    Time frame: Up to 15 years post-BMT

  7. Immune reconstitution as assessed by quantitation of lymphocyte subsets

    Number of participants with quantitative defects in lymphocyte subset numbers following BMT

    Time frame: Up to 15 years post-BMT

  8. Changes in pulmonary function as assessed by pulmonary function testing

    Time frame: Up to 15 years post-BMT

  9. Secondary malignancies

    Number of patients with malignancies following BMT

    Time frame: Up to 15 years post-BMT

  10. Long-term survival

    Time frame: Up to 15 years post-BMT

07

Study locations

13 sites
08

References and documents

Publications

  • Bhoopalan SV, Wlodarski M, Reiss U, Triplett B, Sharma A. Reduced-intensity conditioning-based hematopoietic cell transplantation for dyskeratosis congenita: Single-center experience and literature review. Pediatr Blood Cancer. 2021 Oct;68(10):e29177. doi: 10.1002/pbc.29177. Epub 2021 Jun 4. PubMed 34086408 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2012 (actual). Primary completion is estimated for Dec 2026, 173 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2012
First posted
Aug 8, 2012
StartActual
Jul 2012
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2034
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01659606
Responsible party
Suneet Agarwal (Associate Professor of Pediatrics, Boston Children's Hospital) — Principal investigator
First posted
Aug 8, 2012
Start date
Jul 2012
Primary completion
Dec 2026 (estimated)
Completion
Dec 2034 (estimated)
Last update
Mar 27, 2026

Study contacts

Suneet Agarwal, MD, PHD
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alemtuzumab · Fludarabine · Cyclosporins · Mycophenolic Acid · Tacrolimus

Start the discussion